Table 2. General characteristics of mice among different treatment groupsa

Animal Numbers Beginning/EndBody Weight (g)Blood Glucose (mg/dl)KW (g) EndKW/BW (×10−3) EndSerum Creatinine (mg/dl) End
BeginningEndBeginningbEnd
a KW, kidney weight; BW, body weight; UNx, uninephrectomized; STZ, streptozotosin; nt, not tested.
b One week after STZ injection.
c P < 0.05 versus normal controls.
d P < 0.05 versus pcDNA3.
Normal control (12 wk)6 /626.0 ± 0.840.0 ± 1.799.0 ± 10.5107.0 ± 13.10.28 ± 0.017.0 ± 1.20.17 ± 0.02
UNx-STZ + pcDNA3 (4 wk)3 /325.7 ± 0.926.8 ± 1.5c478.1 ± 35.8481.0 ± 40.2c0.54 ± 0.0219.6 ± 0.7cnt
UNx-STZ + pCMV-HGF (4 wk)4 /425.0 ± 0.927.7 ± 1.2c475.8 ± 43.3469.4 ± 47.9c0.49 ± 0.0218.0 ± 0.8cdnt
UNx-STZ + pcDNA3 (12 wk)9 /625.9 ± 0.528.2 ± 3.5c484.9 ± 43.9489.0 ± 37.6c0.60 ± 0.0521.3 ± 2.9c0.22 ± 0.02c
UNx-STZ + pCMV-HGF (12 wk)8 /826.1 ± 0.929.7 ± 4.9c479.6 ± 38.6461.7 ± 42.5c0.54 ± 0.0318.3 ± 2.5cd0.20 ± 0.02